Alkermes' depression treatment fails to get FDA panel backing
(Reuters) – An advisory panel to the U.S. Food and Drug Administration on Thursday voted against approving Alkermes Plc’s treatment for depression in patients with an inadequate response to standard antidepressant therapies. The decision comes two days after FDA staff reviewers bit.ly/2QegxPF flagged abuse potential for the opioid-based depression treatment and raised questions on its… Read More »